ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Genetic Counseling in African American Women

This study is currently recruiting participants.
Verified by University of Pennsylvania, March 2007

Sponsors and Collaborators: University of Pennsylvania
Department of Defense
Information provided by: University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00419510
  Purpose

The objectives of this study are to develop a Culturally Tailored Genetic (CTGC) protocol for African American women and evaluate its impact on decision making and satisfaction about BRCA1/2 testing, quality of life, and cancer control practices compared to Standard Genetic Counseling (SGC). A secondary objective of this study is to identify African American women who are most and least likely to benefit from CTGC vs. SGC.


Condition Intervention
Breast Cancer
Ovarian Cancer
Behavioral: Culturally Tailored Genetic Counseling

Genetics Home Reference related topics:   breast cancer   

MedlinePlus related topics:   Breast Cancer    Cancer    Genetic Counseling    Ovarian Cancer   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Educational/Counseling/Training, Randomized, Open Label, Active Control, Single Group Assignment
Official Title:   Genetic Counseling for Breast Cancer Susceptibility in African American Women

Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Psychological functioning
  • Cancer screening behaviors
  • Cancer risk reduction behaviors

Estimated Enrollment:   360
Study Start Date:   February 2003
Estimated Study Completion Date:   August 2007

Detailed Description:

Five to 10% of all breast cancer cases have been attributed to two breast ovarian cancer susceptibility genes called BRCA1 and BRCA2 (BRCA1/2). Genetic counseling and testing for BRCA1/2 mutations is now available through clinical research programs using standard counseling protocols. The goal of pre test counseling is to facilitate informed decision making about whether to be tested and to prepare participants for possible outcomes. The goal of post test counseling is to provide information about risk status, recommendations for surveillance, and options for prevention. However, previous research suggests that African American and Caucasian women differ in their attitudes about and responses to pre test education and counseling. Increasingly, cultural beliefs and values are being recognized as important factors in genetic counseling. Despite recommendations to increase the cultural sensitivity of breast cancer risk counseling, such programs have not been developed or evaluated. Therefore, the purpose of this study is to develop a Culturally Tailored Genetic Counseling (CTGC) protocol for African American women and evaluate its impact on psychological functioning and health behaviors compared with Standard Genetic Counseling (SGC) in a randomized clinical trial.

  1. To evaluate the relative impact of CTGC vs. SGC on decision making and satisfaction about BRCA1/2 testing. Compared to SGC, CTGC will lead to higher rates of test acceptance and satisfaction with testing decisions. These effects will be mediated by increases in perceived benefits and decreases in perceived limitations and risks of genetic testing.
  2. To evaluate the impact of CTGC vs. SGC on quality of life and health behaviors following BRCA1/2 testing. Compared to SGC, CTGC will lead to larger decreases in general and cancer specific distress, greater increases in adherence to cancer screening guidelines, and lower rates of prophylactic surgery. Reductions in psychological distress will be mediated by increased use of spiritual coping strategies.

Secondary Aim

To identify African American women who are most and least likely to benefit from CTGC vs. SGC. We predict that the relative benefits of CTGC will be greatest for women with greater endorsement of African American cultural values and those identified as BRCA1/2 carriers.

  Eligibility
Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • Female
  • African American or Black
  • 5% to 10% prior probability of having a BRCA1 or BRCA2 mutation

Exclusion Criteria:

  • Men
  • Individuals who are not African American or Black
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00419510

Contacts
Contact: Chanita Hughes-Halbert, Ph.D.     215-746-7144     chanita@mail.med.upenn.edu    

Locations
United States, Pennsylvania
University of Pennsylvania     Recruiting
      Philadelphia, Pennsylvania, United States, 19104
      Contact: Chanita Hughes-Halbert, Ph.D.     215-746-7144     chanita@mail.med.upenn.edu    

Sponsors and Collaborators
University of Pennsylvania
Department of Defense

Investigators
Principal Investigator:     Chanita Hughes-Halbert, Ph.D.     University of Pennsylvania    
  More Information

Study ID Numbers:   704355, DAMD17-00-1-0262
First Received:   January 4, 2007
Last Updated:   March 21, 2007
ClinicalTrials.gov Identifier:   NCT00419510
Health Authority:   United States: Institutional Review Board

Keywords provided by University of Pennsylvania:
Genetic counseling  
BRCA1 and BRCA2  
African American  

Study placed in the following topic categories:
Ovarian cancer
Ovarian Neoplasms
Disease Susceptibility
Skin Diseases
Gonadal Disorders
Genital Neoplasms, Female
Breast Neoplasms
Endocrine System Diseases
Urogenital Neoplasms
Ovarian Diseases
Genital Diseases, Female
Endocrinopathy
Genetic Predisposition to Disease
Breast Diseases
Endocrine Gland Neoplasms

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site
Adnexal Diseases

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers